While the preventive vaccine accounts for only 5 % of the global pharmaceuticals market, there has been a substantial growth in the recent years as a result of rising incidences of HIV cases and cancer. World Health Organization growth estimations indicate the market may increase at a tremendous rate with the introduction of new therapeutic preventive, and adult vaccines.
North America Preventive Vaccine Market is a $14.57 Billion market in 2018 and is expected to reach $ 26.32 billion by the end of 2023 with a CAGR of 12.56 %.
Vaccination is process of injecting the vaccine given to stimulate the immune system of individual. Vaccine market despite of being a small one is being exploited by the multinational companies owing to its growth at a faster rate. There are as many as 120 new vaccines in the pipeline of many major companies and are set hit the market worldwide in the coming years.
Rise in the frequency of occurrence of infectious diseases, invention of new vaccines for every other disease and increase in the funding for vaccines development helps in driving the growth of preventive vaccine market. And also, rise of investments in R&D department by the major players, technological advancements and increasing occurrence of disease are also helping the growth of the market. Factors like huge capital investment, strict regulatory policies and high cost of treatment are hindering the growth of the market.
North America Preventive Vaccine Market is categorised by type as Live, attenuated vaccines, conjugate vaccine, inactivated vaccines, Toxoid Vaccine, subunit vaccine, Recombinant vector vaccine and DNA vaccine. On the basis of age group, market is divided as Adult Vaccine (Zoster, Influenza, Hepatitis, Cervical Cancer and others) and Paediatric Vaccine (Varicella, MMR, HIB, hepatitis, Poliovirus, Pneumococcal and others. In addition on the basis geography the market is studied under various regions of North America such as US and Canada. Currently, North America enjoys the major share of the therapeutic vaccine market as a result of presence of advanced and active R&D establishment in the region.
Multinational vaccine companies historically have conducted much of the innovation, research, and development in the field of vaccine production. They have used significant revenues are GlaxoSmithKline, plc., Bavarian Nordic, Merck and Company, CSL Limited, Novartis AG, Emergent BioSolutions Inc., Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Vaccine Type
5.1.1 Live, Attenuated Vaccines
5.1.2 Inactivted Vaccines
5.1.3 Toxoid Vaccines
5.1.4 Subunit vaccines
5.1.5 Conjugate vaccines
5.1.6 DNA vaccines
5.1.7 Recombinant vector vaccines
5.2 By End User
5.2.1 Paediatric Vaccine
5.2.1.1 Pneumococcal
5.2.1.2 MMR
5.2.1.3 Varicella
5.2.1.4 Hepatitis
5.2.1.5 Poliovirus
5.2.1.6 HIB
5.2.1.7 Others
5.2.2 Adult Vaccines
5.2.2.1 Influenza
5.2.2.2 Cervical Cancer
5.2.2.3 Hepatitis
5.2.2.4 Zoster
5.2.2.5 Others
6.1 Introduction
6.2 United States
6.3 Canada
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 GlaxoSmithKline, plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent BioSolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune, LLC
8.9 Pfizer, Inc.
8.10 Sanofi Pasteur
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
